semaglutide radnor Semaglutide - CoreAge Rx

Appl Microbiol Biotechnol 2017;101(12):5115-5130

Trial registration ClinicalTrials.gov identifier NCT02146079

Semaglutide does not alter the structure or long-term function of your ovaries, uterus, or other reproductive organs

Gastrointestinal effectsparticularly nausea, vomiting, diarrhea, and constipationaffect 40-50% of patients, especially during dose escalation

1 Semaglutide may cause fetal harm and should be discontinued at least two months before a planned pregnancy

In clinical trials, participants who used semaglutide GLP-1, the active ingredient in Ozempic, for weight management experienced significant weight loss within a relatively short period